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Vector control with long-lasting insecticidal nets (LLINs) and indoor residual spraying are 14 
responsible for more than two thirds of the reduction seen in malaria prevalence in Africa 15 
over the last 15 years (1). Yet the behavioral plasticity of mosquito vectors can lead to 16 
residual transmission and possibly hamper elimination efforts (2, 3).  17 
One identified source of residual transmission is partial zoophagy. Mosquitoes that feed on 18 
peridomestic livestock can avoid contact with insecticides and survive to continue 19 
transmission once human blood is available again (3). This behavioral pattern could be seen 20 
after the scale-up of LLINs that put selective pressure on vectors that bite predominantly 21 
humans indoors (4), either by allowing a shift to a vector species with different behavior (5) 22 
or by selecting members of the same species that circumvent LLINs by biting outdoors (6) or 23 
outside sleeping hours (7). 24 
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Ivermectin is an endectocide, a drug that kills ectoparasites that feed on treated subjects. 25 
Ivermectin mass drug administration to humans has been proposed as a potential 26 
complementary measure to reduce malaria transmission (8). Additional treatment of 27 
peridomestic livestock with ivermectin could reduce malaria transmission by killing partially 28 
zoophagic vectors (9) and also contribute to human wellbeing via the one-health concept, 29 
improving food production and economic benefits of animal owners (10).  30 
Ivermectin, however, has a relatively short half-life (3.5 days in pigs (11) and 2.8 days in 31 
cattle (12)), although veterinary use allows more flexibility in dose and route of 32 
administration. Even novel injectable formulations at 3.15% used at a three-fold dose would 33 
only sustain mosquito-killing concentrations for maximum estimated 40 days in cattle (13). 34 
Consideration should be given to longer-lasting formulations specifically conceived for 35 
vector control.  36 
We previously showed that subcutaneous long-lasting formulations sustained mosquito-37 
killing ivermectin levels in a rabbit model for more than six months (14). Using the same 38 
formulations, we aimed at achieving stable and safe ivermectin levels in a larger mammal, 39 
the pig.  40 
Methods. We chose two 80-kg hybrid mini pigs to facilitate extrapolation to larger 41 
livestock such as cattle. We tested the two formulations of subcutaneous silicone rods that 42 
showed the most promising pharmacokinetic profile in our previous experiment (14). The 43 
rods are 40 mm long and have a 1 mm radius; four or five devices are inserted 44 
subcutaneously in the back or thighs by means of a trocar used for commercially available 45 
hormonal implants. Formulation “F” contains 80% ivermectin (29 mg), 7% sucrose and 13% 46 
deoxycholate. Formulation “X” contains 35% ivermectin (13 mg), 10% sucrose and 55% 47 
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deoxycholate, which greatly increases the elution of the drug (for further details on implant 48 
design refer to (14) ).   49 
Plasma ivermectin levels were measured weekly for 12 weeks after the first month. At 50 
completion of the experiment, the implants were removed and the ivermectin remaining in 51 
the rods quantified. Animals were checked daily for toxicity. The protocol was approved by 52 
the Institutional Animal Care and Use Committee of the University of Navarra. 53 
Results. The implants sustained stable ivermectin plasma levels around 20 ng/ml for 54 
more than 12 weeks (Figure 1), greatly exceeding 6 ng/ml, the concentration needed to kill 55 
50% of Anopheles gambiae mosquitoes in 10 days (15). Both formulations showed a similar 56 
pharmacokinetic pattern, formulation “F” eluted 47% of its ivermectin content while 57 
formulation “X” eluted 55%. The mean daily dose received by the pig with formulation “F” 58 
was 43 mcg/kg/day and for that with formulation “F” 9.8 mcg/kg/day. No clinical adverse 59 
effects were seen in the pigs.  60 
Conclusion. Our results show there is potential to safely sustain mosquitocidal levels 61 
of ivermectin in larger mammals for months using a subcutaneous formulation. Whether an 62 
entomologically relevant outcome can be expected should be tested by means of a cluster 63 
randomized trial. This approach could contribute to human wellbeing not only by reducing 64 
residual malaria transmission driven by zoophagic vectors but also by improving the health 65 
of economically relevant livestock. Hence this intervention could be attractive for livestock 66 
owners, possibly opening the door for previously unforeseen funding collaborations. 67 
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Legend  132 
FIG. 1. Ivermectin plasma levels after implantation of a slow release formulation in two 133 
80 kg-pigs. Levels above the 10-day lethal concentration 50 for An. gambiae (double blue 134 
line) are sustained for at least 12 weeks. We expect this effect to last for at least 6 months 135 
given that the implants still contained 45-53% of ivermectin after removal at 12 weeks. The 136 
dotted lines are included for comparison; red reflects the approximate PK of a single 137 
subcutaneous 300 mcg/kg dose of 1% ivermectin in pigs (11), orange reflects the 138 
approximate PK of a single subcutaneous 630 mcg/kg dose of 3.15% ivermectin in cattle 139 
(13). 140 

